Retina

Data may inform clinical associations, mechanistic research, trial design.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

The US and German collaborative study found performing vitrectomy with silicone oil tamponade to manage postoperative endophthalmitis led to a significant improvement in visual acuity (VA) and had a low complication rate.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team about clinical characteristics of macular holes that close without surgery at the 2023 ASRS annual meeting.

The partnership will drive Kiora's development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team to share information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.

During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.

According to the company, a pair of presentations at the American Society of Retina Specialists annual meeting in Seattle highlight CLS-AX as a promising wet AMD treatment with a new mechanism of action and the potential for longer duration of effect than current therapies.

Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

The company noted at the American Society of Retina Specialists meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.

Lim and colleagues conducted a retrospective study to establish the normalized NBFI using OCTA and test if that index is sufficiently sensitive for detecting early DR.

Researchers found that using automated methods to determine the VA showed “robust performance in predicting visual impairment”

The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.

According to the companies, this partnership will leverage RetinAI's innovative digital health technologies and RCA's network of clinics to analyze real-world health clinical and imaging data.

For visual recovery to occur, there must be photoreceptors left that can be rescued.

According to a study, the experimental eye drop treatment was twice as effective as the standard injection therapy at reducing swelling and improving blood flow within the retina of mice with RVO.

According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

According to the companies, R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery. It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells.

A study found the approach identifies high-risk patients so all preemies don’t need to undergo an invasive eye exam.

Clinical trial investigator Victor H. Gonzalez, MD, presented data at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California.

Results reported in JAMA Ophthalmology show that about 20% of those with diabetic retinopathy have a case that could threaten their vision.